Abstract
Interventions that target fundamental aging processes have the potential to transform human health and health care. A variety of candidate drugs have emerged from basic and translational research that may target aging processes. Some of these drugs are already in clinical use for other purposes, such as metformin and rapamycin. However, designing clinical trials to test interventions that target the aging process poses a unique set of challenges. This paper summarizes the outcomes of an international meeting co-ordinated by the NIH-funded Geroscience Network to further the goal of developing a translational pipeline to move candidate compounds through clinical trials and ultimately into use. We review the evidence that some drugs already in clinical use may target fundamental aging processes. We discuss the design principles of clinical trials to test such interventions in humans, including study populations, interventions, and outcomes. As examples, we offer several scenarios for potential clinical trials centered on the concepts of health span (delayed multimorbidity and functional decline) and resilience (response to or recovery from an acute health stress). Finally, we describe how this discussion helped inform the design of the proposed Targeting Aging with Metformin study.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1424-1434 |
| Number of pages | 11 |
| Journal | Journals of Gerontology - Series A Biological Sciences and Medical Sciences |
| Volume | 71 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2016 |
Fingerprint
Keywords
- Acarbose
- Aging
- Clinical trials
- Metformin
- Rapamycin
ASJC Scopus subject areas
- Aging
- Geriatrics and Gerontology
Cite this
Strategies and Challenges in Clinical Trials Targeting Human Aging. / Newman, John C.; Milman, Sofiya; Hashmi, Shahrukh K.; Austad, Steve N.; Kirkland, James L.; Halter, Jeffrey B.; Barzilai, Nir.
In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 71, No. 11, 01.11.2016, p. 1424-1434.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Strategies and Challenges in Clinical Trials Targeting Human Aging
AU - Newman, John C.
AU - Milman, Sofiya
AU - Hashmi, Shahrukh K.
AU - Austad, Steve N.
AU - Kirkland, James L.
AU - Halter, Jeffrey B.
AU - Barzilai, Nir
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Interventions that target fundamental aging processes have the potential to transform human health and health care. A variety of candidate drugs have emerged from basic and translational research that may target aging processes. Some of these drugs are already in clinical use for other purposes, such as metformin and rapamycin. However, designing clinical trials to test interventions that target the aging process poses a unique set of challenges. This paper summarizes the outcomes of an international meeting co-ordinated by the NIH-funded Geroscience Network to further the goal of developing a translational pipeline to move candidate compounds through clinical trials and ultimately into use. We review the evidence that some drugs already in clinical use may target fundamental aging processes. We discuss the design principles of clinical trials to test such interventions in humans, including study populations, interventions, and outcomes. As examples, we offer several scenarios for potential clinical trials centered on the concepts of health span (delayed multimorbidity and functional decline) and resilience (response to or recovery from an acute health stress). Finally, we describe how this discussion helped inform the design of the proposed Targeting Aging with Metformin study.
AB - Interventions that target fundamental aging processes have the potential to transform human health and health care. A variety of candidate drugs have emerged from basic and translational research that may target aging processes. Some of these drugs are already in clinical use for other purposes, such as metformin and rapamycin. However, designing clinical trials to test interventions that target the aging process poses a unique set of challenges. This paper summarizes the outcomes of an international meeting co-ordinated by the NIH-funded Geroscience Network to further the goal of developing a translational pipeline to move candidate compounds through clinical trials and ultimately into use. We review the evidence that some drugs already in clinical use may target fundamental aging processes. We discuss the design principles of clinical trials to test such interventions in humans, including study populations, interventions, and outcomes. As examples, we offer several scenarios for potential clinical trials centered on the concepts of health span (delayed multimorbidity and functional decline) and resilience (response to or recovery from an acute health stress). Finally, we describe how this discussion helped inform the design of the proposed Targeting Aging with Metformin study.
KW - Acarbose
KW - Aging
KW - Clinical trials
KW - Metformin
KW - Rapamycin
UR - http://www.scopus.com/inward/record.url?scp=84994460732&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994460732&partnerID=8YFLogxK
U2 - 10.1093/gerona/glw149
DO - 10.1093/gerona/glw149
M3 - Review article
C2 - 27535968
AN - SCOPUS:84994460732
VL - 71
SP - 1424
EP - 1434
JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences
JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences
SN - 1079-5006
IS - 11
ER -